<bill session="118" type="h" number="1315" updated="2024-07-24T15:22:50Z">
  <state datetime="2023-03-01">REFERRED</state>
  <status>
    <introduced datetime="2023-03-01"/>
  </status>
  <introduced datetime="2023-03-01"/>
  <titles>
    <title type="display">PC&#226;&#8364;&#8220;CARE Act</title>
    <title type="short" as="introduced">PC&#226;&#8364;&#8220;CARE Act</title>
    <title type="short" as="introduced">Prostate Cancer Community Assistance, Research and Education Act of 2023</title>
    <title type="official" as="introduced">To amend the Public Health Service Act to establish a Prostate Cancer Coordinating Committee, and for other purposes.</title>
  </titles>
  <sponsor bioguide_id="M001210"/>
  <cosponsors>
    <cosponsor bioguide_id="N000147" joined="2024-02-28"/>
    <cosponsor bioguide_id="P000614" joined="2023-12-15"/>
  </cosponsors>
  <actions>
    <action datetime="2023-03-01">
      <text>Introduced in House</text>
    </action>
    <action datetime="2023-03-01" state="REFERRED">
      <text>Referred to the House Committee on Energy and Commerce.</text>
    </action>
    <action datetime="2023-03-10">
      <text>Referred to the Subcommittee on Health.</text>
    </action>
  </actions>
  <committees>
    <committee code="HSIF" name="House Energy and Commerce" subcommittee="" activity="Referral"/>
    <committee code="HSIF14" name="House Energy and Commerce" subcommittee="Health" activity="Referral"/>
  </committees>
  <relatedbills/>
  <subjects>
    <term name="Health"/>
  </subjects>
  <amendments/>
  <summary date="2023-04-21T00:21:36Z" status="Introduced in House">Prostate Cancer Community Assistance, Research and Education Act of 2023 or the PC-CARE Act

This bill establishes a committee to develop, implement, and periodically revise a plan to coordinate federal activities and programs concerning prostate cancer, including those related to research, screening, diagnosis, and treatment.

Committee members must include representatives from specified federal agencies, as well as researchers, clinicians, individuals living with prostate cancer (or their caregivers), and other stakeholders. In addition, at least half of the members must be physicians.</summary>
</bill>
